MCAM Antibodies

Structure of MCAM

MCAM is a single-pass transmembrane glycoprotein with a molecular weight of approximately 70-75 kDa, and its precise weight varies depending on the degree of glycosylation modification.

This protein is composed of 647 amino acids, and its primary structure forms a long extracellular region, a transmembrane region and a short intracellular tail. The secondary structure of MCAM is mainly composed of β -folds, which form the immunoglobulin-like domain (V-V-C2-C2-C2) in its extracellular region, thereby mediating specific adhesion interactions between cells and between cells and the matrix.

Fig. 1 Network of the top 10 genes correlated with MCAM.¹

Key structural properties of MCAM:

• Extracellular region contains five immunoglobulin sample structure domain (V - V - C2 - C2 - C2)
• The transmembrane single α -helical structure is anchored to the cell membrane
• The shorter intracellular tail is involved in intracellular signal transduction

Functions of MCAM

The main function of the MCAM protein is to mediate cell adhesion and signal transduction. However, it is also widely involved in various pathophysiological processes, especially playing a key role in tumorigenesis and angiogenesis.

The adhesion function of MCAM does not rely on calcium ions, which contrasts with calcium-dependent classical cadherins and highlights its particular advantages in rapid and dynamic cell migration, such as tumor cell invasion.

Applications of MCAM and MCAM Antibody in Literature

1. Yang, et al. "Mcam inhibits macrophage-mediated development of mammary gland through non-canonical Wnt signaling." Nature Communications 15.1 (2024): 36. https://doi.org/10.1038/s41467-023-44338-0

This study found through screening that MCAM is a negative regulatory factor of mammary epithelial cells (MEC). Knockout of MCAM can recruit macrophages through the Il4-Stat6 axis, promote their secretion of Wnt5a, and thereby activate the non-classical Wnt pathway receptor Ryk, thereby enhancing the proliferation and differentiation ability of MEC, revealing a new mechanism by which MCAM regulates breast development through the Wnt5a/Ryk axis.

2. Joshkon, Ahmad, et al. "Role of CD146 (MCAM) in physiological and pathological angiogenesis—contribution of new antibodies for therapy." Biomedicines 8.12 (2020): 633. https://doi.org/10.3390/biomedicines8120633

The article indicates that MCAM is an immunoglobulin superfamily adhesion molecule, and its soluble form plays a key role in physiological and pathological angiogenesis. The levels are significantly elevated in patients with various diseases. Monoclonal antibodies targeting MCAM have become a potential therapeutic strategy to block its pathogenic effects.

3. Luo, Wen, et al. "Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma." Molecular Therapy Oncology 32.4 (2024). https://doi.org/10.1016/j.omton.2024.200894

The article indicates that MCAM is an immunoglobulin superfamily adhesion molecule, and its soluble form plays a key role in physiological and pathological angiogenesis. The levels are significantly elevated in patients with various diseases. Monoclonal antibodies targeting MCAM have become a potential therapeutic strategy to block its pathogenic effects.

4. Wang, Weijun, et al. "Intestinal epithelium-specific Fut2 deficiency promotes colorectal cancer through down-regulating fucosylation of MCAM." Journal of translational medicine 21.1 (2023): 82. https://doi.org/10.1186/s12967-023-03906-0

This study reveals that the Fut2 gene defect promotes the occurrence and development of colorectal cancer (CRC) by down-regulating the fucosylation modification of the MCAM protein. In both in vivo and in vitro experiments, the absence of Fut2 led to a decrease in the fucosylation level of MCAM, thereby enhancing the proliferation, invasion and metastasis capabilities of cancer cells. The results indicate that targeting MCAM glycosylation may be a potential therapeutic strategy for FUT2-deficient CRC.

5. Du, Q Zhang, S Wang, et al. "MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration." Journal of Clinical Laboratory Analysis 36.2 (2022): e24214. https://doi.org/10.1002/jcla.24214

This study, through bioinformatics analysis, found that high expression of MCAM was significantly associated with poor prognosis and metastasis risk in patients with osteosarcoma. Functional experiments have confirmed that MCAM can regulate tumor cell migration. The results indicate that MCAM is a potential prognostic biomarker for osteosarcoma, and its expression level is helpful for assessing the risk of metastasis.

Creative Biolabs: MCAM Antibodies for Research

Creative Biolabs specializes in the production of high-quality MCAM antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MCAM Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MCAM antibodies, custom preparations, or technical support, contact us at email.